Treatment of vaginitis caused by non-albicans Candida species

References

• Kumari V, Banerjee T, Kumar P, Pandey S, Tilak R. Emergence of non-albicans candida among candidal vulvovaginitis cases and study of their potential virulence factors, from a tertiary care center, North India. Indian J Pathol Microbiol. 2013 Apr;56(2):144–147. doi: 10.4103/0377-4929.118703. PMID: 24056652.
   PubMed Web of Science ®Google Scholar
• Babic M, Hukic M. Candida albicans and non-albicans species as etiological agent of vaginitis in pregnant and non-pregnant women. Bosn J Of Basic Med Sci. 2010 Feb;10(1):89–97. doi: 10.17305/bjbms.2010.2744. PMID: 20192939; PMCID: PMC5596619.
   PubMed Web of Science ®Google Scholar
• Makanjuola O, Bongomin F, Fayemiwo SA. An update on the roles of non-albicans candida species in vulvovaginitis. J Fungi. 2018 Oct 31;4(4):121. doi: 10.3390/jof4040121. PMID: 30384449; PMCID: PMC6309050.
   Web of Science ®Google Scholar
• Mahmoudi Rad M, Zafarghandi S, Abbasabadi B, et al. The epidemiology of candida species associated with vulvovaginal candidiasis in an Iranian patient population. Eur J Obstet Gynecol Reprod Biol. 2011 Apr;155(2):199–203. doi: 10.1016/j.ejogrb.2010.11.022. Epub 2010 Dec 30. PMID: 21194828.
   PubMed Web of Science ®Google Scholar
• Gunther LS, Martins HP, Gimenes F, Abreu AL, Consolaro ME, Svidzinski TI. Prevalence of Candida albicans and non-albicans isolates from vaginal secretions: comparative evaluation of colonization, vaginal candidiasis and recurrent vaginal candidiasis in diabetic and non-diabetic women. Sao Paulo Med J. 2014;132(2):116–120. doi: 10.1590/1516-3180.2014.1322640. PMID: 24714993.
   PubMed Web of Science ®Google Scholar
• Vermitsky JP, Self MJ, Chadwick SG, et al. Survey of vaginal-flora candida species isolates from women of different age groups by use of species-specific PCR detection. J Clin Microbiol. 2008 Apr;46(4):1501–1503. doi: 10.1128/JCM.02485-07. Epub 2008 Feb 27. PMID: 18305136; PMCID: PMC2292962.
   PubMed Web of Science ®Google Scholar
• Hettiarachchi N, Ashbee HR, Wilson JD. Prevalence and management of non-albicans vaginal candidiasis. Sex Transm Infect. 2010 Apr;86(2):99–100. doi: 10.1136/sti.2009.040386. Erratum in: Sex Transm Infect. 2010 Jun;86(3):250. Hetticarachchi, Nalin [corrected to Hettiarachchi, Nalin]. PMID: 20332368.
   PubMed Web of Science ®Google Scholar
• Spinillo A, Capuzzo E, Gulminetti R, Marone P, Colonna L, Piazzi G. Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. Am J Obstet Gynecol. 1997 Jan;176(1 Pt 1):138–141. doi: 10.1016/s0002-9378(97)80026-9. PMID: 9024104.
   PubMed Web of Science ®Google Scholar
• Marchaim D, Lemanek L, Bheemreddy S, et al. 2012 Dec;120(6):1407–1414. doi: 10.1097/aog.0b013e31827307b2. PMID: 23168767.
   Google Scholar
• Farr A, Effendy I, Tirri BF, Hof H, Mayser P, Petricevic L, Ruhnke M, Schaller M, Schäfer APA, Willinger B, Mendling W. Vulvovaginal candidosis (excluding Mucocutaneous candidosis): guideline of the German (DGGG), Austrian (OEGGG) and Swiss (SGGG) Society of Gynecology and Obstetrics (S2k-level, AWMF registry number 015/072, September 2020). Geburtshilfe Frauenheilkd. 2021 Apr;81(4):398–421. doi: 10.1055/a-1345-8793. Epub 2021 Apr 14. PMID: 33867561; PMCID: PMC8046514.
   PubMedGoogle Scholar
• Saxon Lead Author GDGC, Edwards A, Rautemaa-Richardson R, Owen C, Nathan B, Palmer B, Wood C, Ahmed H, Ahmad Patient Representatives S, FitzGerald Ceg Editor M. British association for sexual health and HIV national guideline for the management of vulvovaginal candidiasis (2019). Int J STD AIDS. 2020 Oct;31(12):1124–1144. doi: 10.1177/0956462420943034. Epub 2020 Sep 3. PMID: 32883171.
   PubMed Web of Science ®Google Scholar
• Brown L, Chamula M, Weinberg S, et al. Compliance with the updated BASHH recurrent vulvovaginal candidiasis guidelines improves patient outcomes. J Fungi. 2022 Aug 30;8(9):924. doi: 10.3390/jof8090924. PMID: 36135648; PMCID: PMC9503580
   Web of Science ®Google Scholar
• Ignjatović A, Arsić-Arsenijević V, Golubović M, et al. Recurrent vulvovaginal candidosis and cluster analysis of clinical signs and symptoms: a Laboratory-Based Investigation. J Fungi. 2020 Jul 22;6(3):113. doi: 10.3390/jof6030113. PMID: 32707751; PMCID: PMC7559823.
   Web of Science ®Google Scholar
• Parazzini F, Di Cintio E, Chiantera V, et al. Determinants of different candida species infections of the genital tract in women. Sporachrom study Geoup. Eur J Obstet Gynecol Reprod Biol. 2000 Dec;93(2):141–145. doi: 10.1016/s0301-2115(00)00289-x. PMID: 11074134.
   PubMed Web of Science ®Google Scholar
• Benedict K, Moret R, Molinari NAM, Jackson BR, Harville EW. Survey of healthcare providers’ testing practices for vulvovaginal candidiasis and treatment outcomes–United States, 2021. PLOS ONE. 2022 Dec 30;17(12):e0278630. doi: 10.1371/journal.pone.0278630. PMID: 36584109; PMCID: PMC9803167.
   PubMed Web of Science ®Google Scholar
• Phillips NA, Bachmann G, Haefner H, Martens M, Stockdale C. Topical treatment of recurrent vulvovaginal candidiasis: an expert consensus. Womens Health Rep (New Rochelle). 2022 Jan 31;3(1):38–42. doi: 10.1089/whr.2021.0065. PMID: 35136875; PMCID: PMC8812501.
   PubMedGoogle Scholar
• Jallow S, Govender NP. Ibrexafungerp: a first-in-class oral triterpenoid glucan synthase inhibitor. J Fungi. 2021 Feb 25;7(3):163. doi: 10.3390/jof7030163. PMID: 33668824; PMCID: PMC7996284.
   Web of Science ®Google Scholar
• Vandecruys P, Baldewijns S, Sillen M, et al. Oteseconazole: a long-awaited diversification of the antifungal arsenal to manage recurrent vulvovaginal candidiasis (RVVC). Expert Rev Anti Infect Ther. 2023 Jul;21(8):799–812. doi: 10.1080/14787210.2023.2233696. Epub 2023 Jul 24. PMID: 37449774.
   PubMed Web of Science ®Google Scholar
• Whaley SG, Berkow EL, Rybak JM, et al. Azole antifungal resistance in candida albicans and emerging non-albicans Candida species. Front Microbiol. 2017 Jan 12;7:2173. doi: 10.3389/fmicb.2016.02173. PMID: 28127295; PMCID: PMC5226953.
   PubMed Web of Science ®Google Scholar
• Dennerstein GJ, Ellis DH, Reed CS, et al. Pathogenicity of non-albicans yeasts in the vagina. J Low Genit Tract Dis. 2011 Jan;15(1):33–36. doi: 10.1097/LGT.0b013e3181d94f39. PMID: 21192174.
   PubMed Web of Science ®Google Scholar
• Kennedy MA, Sobel JD. Vulvovaginal candidiasis caused by non-albicans candida species: new insights. Curr Infect Dis Rep. 2010 Nov;12(6):465–470. doi: 10.1007/s11908-010-0137-9. PMID: 21308556.
   PubMedGoogle Scholar
• Boyd Tressler A, Markwei M, Fortin C, et al. Risks for recurrent vulvovaginal candidiasis caused by non-albicans Candida versus Candida Albicans. J Womens Health (Larchmt). 2021 Nov;30(11):1588–1596. doi: 10.1089/jwh.2020.8811. Epub 2021 Jul 22. PMID: 34292794.
   PubMed Web of Science ®Google Scholar
• File B, Sobel R, Becker M, et al. Fluconazole-resistant Candida albicans vaginal infections at a referral center and treated with boric acid. J Low Genit Tract Dis. 2023 Jul 1;27(3):262–265. doi: 10.1097/LGT.0000000000000733. Epub 2023 Mar 24. PMID: 36961480.
   PubMed Web of Science ®Google Scholar
• Powell AM, Gracely E, Nyirjesy P. Non-albicans Candida Vulvovaginitis: treatment experience at a tertiary care vaginitis center. J Low Genit Tract Dis. 2016 Jan;20(1):85–89. doi: 10.1097/LGT.0000000000000126. PMID: 26083330.
   PubMed Web of Science ®Google Scholar
• Odds FC, Webster CE, Riley VC, et al. Epidemiology of vaginal candida infection: significance of numbers of vaginal yeasts and their biotypes. Eur J Obstet Gynecol Reprod Biol. 1987 May;25(1):53–66. doi: 10.1016/0028-2243(87)90092-x. PMID: 3297841.
   PubMed Web of Science ®Google Scholar
• Rodrigues CF, Silva S, Henriques M. Candida glabrata: a review of its features and resistance. Eur J Clin Microbiol Infect Dis. 2014 May;33(5):673–688. doi: 10.1007/s10096-013-2009-3. Epub 2013 Nov 19. PMID: 24249283.
   PubMed Web of Science ®Google Scholar
• Horowitz BJ. Mycotic vulvovaginitis: a broad overview. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1188–1192. doi: 10.1016/s0002-9378(12)90725-5. PMID: 1951573.
   PubMed Web of Science ®Google Scholar
• Fidel PL Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev. 1999 Jan;12(1):80–96. doi: 10.1128/CMR.12.1.80. PMID: 9880475; PMCID: PMC88907.
   PubMed Web of Science ®Google Scholar
• Redondo-Lopez V, Lynch M, Schmitt C, et al. Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents. Obstet Gynecol. 1990 Oct;76(4):651–655. PMID: 2216197.
   PubMed Web of Science ®Google Scholar
• Richter SS, Galask RP, Messer SA, et al. Antifungal susceptibilities of candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol. 2005 May;43(5):2155–2162. doi: 10.1128/JCM.43.5.2155-2162.2005. PMID: 15872235; PMCID: PMC1153777.
   PubMed Web of Science ®Google Scholar
• Kiasat N, Rezaei-Matehkolaei A, Mahmoudabadi AZ. Microsatellite typing and antifungal susceptibility of Candida glabrata strains isolated from patients with Candida Vaginitis. Front Microbiol. 2019 Jul 31;10:1678. doi: 10.3389/fmicb.2019.01678. PMID: 31417505; PMCID: PMC6685060.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev. 2006 Apr;19(2):435–447. doi: 10.1128/CMR.19.2.435-447.2006. PMID: 16614256; PMCID: PMC1471993.
   PubMed Web of Science ®Google Scholar
• Cavalheiro M, Costa C, Silva-Dias A, Miranda IM, Wang C, Pais P, Pinto SN, Mil-Homens D, Sato-Okamoto M, Takahashi-Nakaguchi A, Silva RM, Mira NP, Fialho AM, Chibana H, Rodrigues AG, Butler G, Teixeira MC. A transcriptomics approach to unveiling the mechanisms of in vitro evolution towards fluconazole resistance of a candida glabrata clinical isolate. Antimicrob Agents Chemother. 2018 Dec 21;63(1):e00995–18. doi: 10.1128/AAC.00995-18. PMID: 30348666; PMCID: PMC6325195.
   PubMed Web of Science ®Google Scholar
• Misas E, Seagle E, Jenkins EN, Rajeev M, Hurst S, Nunnally NS, Bentz ML, Lyman MM, Berkow E, Harrison LH, Schaffner W, Markus TM, Pierce R, Farley MM, Chow NA, Lockhart SR, Litvintseva AP, Hanson KE. Genomic description of acquired fluconazole- and echinocandin-resistance in patients with serial candida glabrata isolates. J Clin Microbiol. 2024 Jan 24;62(2):e0114023. doi: 10.1128/jcm.01140-23. Epub ahead of print. PMID: 38265207.
   PubMed Web of Science ®Google Scholar
• Kasper L, Seider K, Hube B, Bolotin-Fukuhara M. Intracellular survival of candida glabrata in macrophages: immune evasion and persistence. FEMS Yeast Res. 2015 Aug;15(5):fov042. doi: 10.1093/femsyr/fov042. Epub 2015 Jun 10. PMID: 26066553.
   PubMed Web of Science ®Google Scholar
• Zhang L, She X, Merenstein D, et al. Fluconazole resistance patterns in candida species that colonize women with HIV infection. Curr Ther Res Clin Exp. 2014 Sep 28;76:84–89. doi: 10.1016/j.curtheres.2014.07.002. PMID: 25352939; PMCID: PMC4209509.
   PubMedGoogle Scholar
• Alves CT, Wei XQ, Silva S, et al. Candida albicans promotes invasion and colonisation of candida glabrata in a reconstituted human vaginal epithelium. J Infect. 2014 Oct;69(4):396–407. doi: 10.1016/j.jinf.2014.06.002. Epub 2014 Jun 9. PMID: 24924556.
   PubMed Web of Science ®Google Scholar
• Arendrup MC. Candida and candidaemia. Susceptibility and epidemiology. Dan Med J. 2013 Nov;60(11):B4698. PMID: 24192246.
   PubMed Web of Science ®Google Scholar
• Badiee P, Badali H, Boekhout T, et al. Antifungal susceptibility testing of Candida species isolated from the immunocompromised patients admitted to ten university hospitals in Iran: comparison of colonizing and infecting isolates. BMC Infect Dis. 2017 Nov 21;17(1):727. doi: 10.1186/s12879-017-2825-7. PMID: 29157206; PMCID: PMC5697407.
   PubMedGoogle Scholar
• Sobel JD. Treatment of vaginal candida infections. Expert Opin Pharmacother. 2002 Aug;3(8):1059–1065. doi: 10.1517/14656566.3.8.1059. PMID: 12150685.
   PubMedGoogle Scholar
• Krogh-Madsen M, Arendrup MC, Heslet L, et al. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis. 2006 Apr 1;42(7):938–944. doi: 10.1086/500939. Epub 2006 Feb 27. PMID: 16511756.
   PubMed Web of Science ®Google Scholar
• Khan ZU, Ahmad S, Al-Obaid I, Al-Sweih NA, Joseph L, Farhat D. Emergence of resistance to amphotericin B and triazoles in Candida glabrata vaginal isolates in a case of recurrent vaginitis. J Chemotherapy. 2008 Aug;20(4):488–491. doi: 10.1179/joc.2008.20.4.488. PMID: 18676230.
   PubMed Web of Science ®Google Scholar
• Kerridge D, Nicholas RO. Drug resistance in the opportunistic pathogens Candida albicans and Candida glabrata. J Antimicrob Chemother. 1986 Oct;18(Supplement_B):39–49. doi: 10.1093/jac/18.supplement_b.39. PMID: 3539907.
   PubMedGoogle Scholar
• Sobel JD, Chaim W, Nagappan V, et al. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol. 2003 Nov;189(5):1297–1300. doi: 10.1067/s0002-9378(03)00726-9 PMID: 14634557.
   PubMed Web of Science ®Google Scholar
• Choukri F, Benderdouche M, Sednaoui P. In vitro susceptibility profile of 200 recent clinical isolates of candida spp. To topical antifungal treatments of vulvovaginal candidiasis, the imidazoles and nystatin agents. J Mycol Med. 2014 Dec;24(4):303–307. doi: 10.1016/j.mycmed.2014.05.001. Epub 2014 Oct 23. PMID: 25442913.
   PubMed Web of Science ®Google Scholar
• Davies S, Johnson E, White D. How to treat persistent vaginal yeast infection due to species other than Candida albicans: table 1. Sex Transm Infect. 2013 Mar;89(2):165–166. doi: 10.1136/sextrans-2012-050669. Epub 2012 Nov 24. PMID: 23180861.
   PubMed Web of Science ®Google Scholar
• Phillips AJ. Treatment of non-albicans candida vaginitis with amphotericin B vaginal suppositories. Am J Obstet Gynecol. 2005 Jun;192(6):2009–2012; discussion 2012-3. doi: 10.1016/j.ajog.2005.03.034. PMID: 15970877.
   PubMed Web of Science ®Google Scholar
• White DJ, Habib AR, Vanthuyne A, Langford S, Symonds M. Combined topical flucytosine and amphotericin B for refractory vaginal candida glabrata infections. Sex Transm Infect. 2001 Jun;77(3):212–213. doi: 10.1136/sti.77.3.212. PMID: 11402233; PMCID: PMC1744305.
   PubMed Web of Science ®Google Scholar
• Sheikh S, Ahmad A, Ali SM, et al. Lipid-based amphotericin B gel treatment eradicates vulvovaginal candidiasis in patients who failed to azole therapy. Arch Dermatol Res. 2023 Sep;315(7):1939–1944. doi: 10.1007/s00403-023-02583-9. Epub 2023 Mar 1. PMID: 36856855.
   PubMed Web of Science ®Google Scholar
• Morris GC, Dean G, Soni S, et al. Outcomes and experiences of using oral voriconazole with or without concomitant topical agents to treat refractory vulvovaginal yeast infections. Int J STD AIDS. 2022 Nov;33(13):1134–1141. doi: 10.1177/09564624221127356. Epub 2022 Oct 10. PMID: 36214529.
   PubMed Web of Science ®Google Scholar
• Taghinejadi N, Andersson MI, Lord E. Recurrent vulvovaginal candidiasis with Candida glabrata – a management conundrum. Int J STD AIDS. 2022 Sep;33(10):939–942. doi: 10.1177/09564624221118739. Epub 2022 Aug 13. PMID: 35968569.
   PubMed Web of Science ®Google Scholar
• Güzel AB, Aydın M, Meral M, Kalkancı A, Ilkit M. Clinical characteristics of Turkish women with candida krusei vaginitis and antifungal susceptibility of the C. krusei isolates. Infect Dis Obstet Gynecol. 2013;2013:698736. doi: 10.1155/2013/698736. Epub 2013 Dec 11. PMID: 24396265; PMCID: PMC3874352.
   PubMedGoogle Scholar
• Kronen R, Hsueh K, Lin C, et al. Creation and assessment of a clinical predictive calculator and mortality associated with candida krusei bloodstream infections. Open Forum Infect Dis. 2018 Feb 9;5(2):ofx253. doi: 10.1093/ofid/ofx253. PMID: 29450209; PMCID: PMC5808796.
   PubMed Web of Science ®Google Scholar
• Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991 Oct 31;325(18):1274–1277. doi: 10.1056/NEJM199110313251803. PMID: 1669837.
   PubMed Web of Science ®Google Scholar
• Israel S, Amit S, Israel A, et al. The epidemiology and susceptibility of Candidemia in Jerusalem, Israel. Front Cell Infect Microbiol. 2019 Oct 11;9:352. doi: 10.3389/fcimb.2019.00352. PMID: 31681629; PMCID: PMC6801307.
   PubMed Web of Science ®Google Scholar
• Singh S, Sobel JD, Bhargava P, et al. Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. Clin Infect Dis. 2002 Nov 1;35(9):1066–1070. doi: 10.1086/343826. Epub 2002 Oct 10. PMID: 12384840.
   PubMed Web of Science ®Google Scholar
• Arastehfar A, Kargar ML, Mohammadi SR, et al. A high rate of recurrent vulvovaginal candidiasis and therapeutic failure of azole derivatives among Iranian women. Front Microbiol. 2021 Apr 28;12:655069. doi: 10.3389/fmicb.2021.655069. PMID: 33995315; PMCID: PMC8113757.
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Curfs-Breuker I, Meis JF, et al. In vitro antifungal susceptibility testing of candida isolates with the EUCAST methodology, a new method for ECOFF determination. Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02372–16. doi: 10.1128/AAC.02372-16. PMID: 28115353; PMCID: PMC5365691.
   PubMed Web of Science ®Google Scholar
• Lockhart SR, Messer SA, Pfaller MA, et al. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J Clin Microbiol. 2008 Aug;46(8):2659–2664. doi: 10.1128/JCM.00803-08. Epub 2008 Jun 18. PMID: 18562582; PMCID: PMC2519489.
   PubMed Web of Science ®Google Scholar
• Nyirjesy P, Alexander AB, Weitz MV. Vaginal Candida parapsilosis: pathogen or bystander? Infect Dis Obstet Gynecol. 2005 Mar;13(1):37–41. doi: 10.1155/2005/401530. PMID: 16040326; PMCID: PMC1784559.
   PubMedGoogle Scholar
• Xiao M, Fan X, Chen SC, Wang H, Sun ZY, Liao K, Chen SL, Yan Y, Kang M, Hu ZD, Chu YZ, Hu TS, Ni YX, Zou GL, Kong F, Xu YC. Antifungal susceptibilities of candida glabrata species complex, candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. J Antimicrob Chemother. 2015 Mar;70(3):802–810. doi: 10.1093/jac/dku460. Epub 2014 Dec 3. PMID: 25473027.
   PubMed Web of Science ®Google Scholar
• Daneshnia F, de Almeida Júnior JN, Ilkit M, Lombardi L, Perry AM, Gao M, Nobile CJ, Egger M, Perlin DS, Zhai B, Hohl TM, Gabaldón T, Colombo AL, Hoenigl M, Arastehfar A. Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap. Lancet Microbe. 2023 Jun;4(6):e470–e480. doi: 10.1016/S2666-5247(23)00067-8. Epub 2023 Apr 27. Erratum in: Lancet Microbe. 2023 Aug;4(8):e576. PMID: 37121240.
   PubMedGoogle Scholar
• Daneshnia F, Arastehfar A, Lombardi L, et al. Candida parapsilosis isolates carrying mutations outside FKS1 hotspot regions confer high echinocandin tolerance and facilitate the development of echinocandin resistance. Int J Antimicrob Agents. 2023 Jul;62(1):106831. doi: 10.1016/j.ijantimicag.2023.106831. Epub 2023 Apr 28. PMID: 37121442.
   PubMed Web of Science ®Google Scholar
• Sullivan DJ, Moran GP, Pinjon E, Al-Mosaid A, Stokes C, Vaughan C, Coleman DC. Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans. FEMS Yeast Res. 2004 Jan;4(4–5):369–376. doi: 10.1016/S1567-1356(03)00240-X. PMID: 14734017.
   PubMed Web of Science ®Google Scholar
• Shan Y, Fan S, Liu X, et al. Prevalence of Candida albicans-closely related yeasts, candida africana and Candida dubliniensis, in vulvovaginal candidiasis. Med Mycol. 2014 Aug;52(6):636–640. doi: 10.1093/mmy/myu003. Epub 2014 Jul 14. PMID: 25023482.
   PubMed Web of Science ®Google Scholar
• Sobel JD, Vazquez J, Lynch M, et al. Vaginitis due to Saccharomyces cerevisiae: epidemiology, clinical aspects, and therapy. Clin Infect Dis. 1993 Jan;16(1):93–99. doi: 10.1093/clinids/16.1.93. PMID: 8448324.
   PubMed Web of Science ®Google Scholar
• Sasoni N, Caracciolo B, Cabeza MS, et al. Antifungal susceptibility testing following the CLSI M27 document, along with the measurement of MFC/MIC ratio, could be the optimal approach to detect amphotericin B resistance in Clavispora (Candida) lusitaniae. Susceptibility patterns of contemporary isolates of this species. Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0096823. doi: 10.1128/aac.00968-23. Epub 2023 Dec 12. PMID: 38084953; PMCID: PMC10777849.
   PubMed Web of Science ®Google Scholar
• Scott NE, Edwin Erayil S, Kline SE, et al. Rapid evolution of multidrug resistance in a Candida lusitaniae infection during micafungin monotherapy. Antimicrob Agents Chemother. 2023 Aug 17;67(8):e0054323. doi: 10.1128/aac.00543-23. Epub 2023 Jul 10. PMID: 37428075; PMCID: PMC10433866.
   PubMed Web of Science ®Google Scholar
• Silverman NS, Morgan M, Nichols WS. Candida lusitaniae as an unusual cause of recurrent vaginitis and its successful treatment with intravaginal boric acid. Infect Dis Obstet Gynecol. 2001;9(4):245–247. doi: 10.1155/S1064744901000400. PMID: 11916183; PMCID: PMC1784662.
   PubMedGoogle Scholar
• Sobel JD. New antifungals for vulvovaginal candidiasis: what is their role? Clin Infect Dis. 2023 Mar 4;76(5):783–785. doi: 10.1093/cid/ciad002. PMID: 36610791.
   PubMedGoogle Scholar
• Swate TE, Weed JC. Boric acid treatment of vulvovaginal candidiasis. Obstet Gynecol. 1974 Jun;43(6):893–895. PMID: 4597792.
   PubMed Web of Science ®Google Scholar
• Guaschino S, De Seta F, Sartore A, et al. Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2001 Mar;184(4):598–602. doi: 10.1067/mob.2001.111938. PMID: 11262459.
   PubMed Web of Science ®Google Scholar
• De Seta F, Schmidt M, Vu B, Essmann M, Larsen B. Antifungal mechanisms supporting boric acid therapy of candida vaginitis. J Antimicrob Chemother. 2009 Feb;63(2):325–336. doi: 10.1093/jac/dkn486. Epub 2008 Dec 4. PMID: 19059942.
   PubMed Web of Science ®Google Scholar
• Khameneie KM, Arianpour N, Roozegar R, Aklamli M, Amiri MM. Fluconazole and boric acid for treatment of vaginal candidiasis–new words about old issue. East Afr Med J. 2013 Apr;90(4):117–123. PMID: 26866095.
   PubMedGoogle Scholar
• Iavazzo C, Gkegkes ID, Zarkada IM, et al. Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. J Womens Health (Larchmt). 2011 Aug;20(8):1245–1255. doi: 10.1089/jwh.2010.2708. Epub 2011 Jul 20. PMID: 21774671.
   PubMed Web of Science ®Google Scholar
• Mittelstaedt R, Kretz A, Levine M, Handa VL, Ghanem KG, Sobel JD, Powell A, Tuddenham S. Data on safety of intravaginal boric acid use in pregnant and nonpregnant women: a narrative review. Sex Transm Dis. 2021 Dec 1;48(12):e241–e247. doi: 10.1097/OLQ.0000000000001562. Erratum in: Sex Transm Dis. 2022 Jun 1;49(6):e78. PMID: 34561373; PMCID: PMC10100571.
   PubMed Web of Science ®Google Scholar
• Salama OE, Gerstein AC. Differential response of candida species morphologies and isolates to fluconazole and boric acid. Antimicrob Agents Chemother. 2022 May 17;66(5):e0240621. doi: 10.1128/aac.02406-21. Epub 2022 Apr 21. PMID: 35446135; PMCID: PMC9112882.
   PubMed Web of Science ®Google Scholar
• Fernandes Â, Azevedo N, Valente A, et al. Vulvovaginal candidiasis and asymptomatic vaginal colonization in Portugal: epidemiology, risk factors and antifungal pattern. Med Mycol. 2022 May 5;60(5):myac029. doi: 10.1093/mmy/myac029. PMID: 35482711.
   PubMed Web of Science ®Google Scholar
• Fan S, Liu X, Wu C, Xu L, Li J. Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia. 2015 Feb;179(1–2):95–101. doi: 10.1007/s11046-014-9827-4. Epub 2014 Nov 22. PMID: 25416649.
   PubMed Web of Science ®Google Scholar